Altimmune Inc Stock Nasdaq
Equities
US02155H1014
Biotechnology & Medical Research
Sales 2024 * | 31.25M 43.02M | Sales 2025 * | 25M 34.41M | Capitalization | 458M 630M |
---|---|---|---|---|---|
Net income 2024 * | -59M -81.21M | Net income 2025 * | -142M -195M | EV / Sales 2024 * | 12.6 x |
Net cash position 2024 * | 63.88M 87.93M | Net cash position 2025 * | 257M 353M | EV / Sales 2025 * | 8.04 x |
P/E ratio 2024 * |
-7.67
x | P/E ratio 2025 * |
-5.12
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.22% |
Latest transcript on Altimmune Inc
Managers | Title | Age | Since |
---|---|---|---|
Vipin K. Garg
CEO | Chief Executive Officer | 67 | 18-11-29 |
Director of Finance/CFO | 66 | 21-12-30 | |
Anthony Blandin
CMP | Compliance Officer | - | 22-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mitchel Sayare
CHM | Chairman | 76 | 10-03-31 |
Mack Gill
BRD | Director/Board Member | 72 | 04-07-31 |
Philip Hodges
BRD | Director/Board Member | 56 | 03-08-31 |
1st Jan change | Capi. | |
---|---|---|
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |